Guanylin and uroguanylin regulate electrolyte transport in isolated human cortical collecting ducts  by Sinðić, Aleksandra et al.
Kidney International, Vol. 67 (2005), pp. 1420–1427
Guanylin and uroguanylin regulate electrolyte transport in
isolated human cortical collecting ducts
ALEKSANDRA SIN

DIC´, JOCHEN R. HIRSCH, ANA VELIC, HANSJU¨RGEN PIECHOTA,
and EBERHARD SCHLATTER
Medizinische Klinik und Poliklinik D, Experimentelle Nephrologie, Universita¨tsklinikum Mu¨nster, Mu¨nster, Germany; and Klinik
und Poliklinik fu¨r Urologie, Universita¨tsklinikum Mu¨nster, Mu¨nster, Germany
Guanylin and uroguanylin regulate electrolyte transport in iso-
lated human cortical collecting ducts.
Background. Guanylin and uroguanylin link intestinal and
renal electrolyte and water transport. Their function in in-
testine is well studied, but renal actions are less understood.
Uroguanylin concentrations are increased in patients with
chronic renal failure, nephrotic syndrome, or those on dialysis.
Guanylate cyclase C (GC-C) is the receptor first described for
these peptides. In guanylate cyclase C–deficient mice guanylin-
and uroguanylin-induced renal natriuresis, kaliuresis, and di-
uresis are retained.
Methods. Effects of guanylin and uroguanylin on princi-
pal cells of human cortical collecting ducts (CCD) isolated
from kidneys after tumor nephrectomy were investigated. Re-
verse transcription-polymerase chain reaction (RT-PCR), slow
whole-cell patch-clamp, and microfluorimetric analysis of intra-
cellular Ca2+ were used. Here we present first functional mea-
surements of isolated human CCD.
Results. Principal cells of CCD were identified by the
amiloride-induced hyperpolarization of principal cells (−3.8 ±
0.3 mV) (N = 52). Cells depolarized upon guanylin or
uroguanylin (each 10 nmol/L) by 3.3 ± 0.8 mV (N = 12) and
3.4 ± 0.5 mV (N = 18), respectively, but were hyperpolarized
by 8Br-cyclic guanosine monophosphate (cGMP) (100 lmol/L)
(−3.0 ± 0.2 mV) (N = 4). mRNA for GC-C was not detected
in CCD. Effects of both peptides were inhibited by Ba2+
(1 mmol/L) or phospholipase A2 (PLA2) inhibition (AA-
COCF3) (5 lmol/L).
Conclusion. These findings suggest a new cGMP- and GC-C–
independent but PLA2-dependent signaling pathway for these
peptides in the kidney. Most likely guanylin and uroguanylin in-
hibit luminal K+ channels of principal cells of human CCD via
this pathway. This depolarization of principal cells consequently
reduces the driving force of Na+ and water reabsorption, ex-
plaining natriuresis and diuresis caused by these peptides.
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The existence of intestinal natriuretic peptides was pro-
posed by the work of Lennane et al in 1975 [1] who
showed that salt taken orally induces higher natriure-
sis than an intravenous salt load. Increased salt ingestion
leads to secretion of guanylin and/or uroguanylin into the
intestinal lumen [2, 3] and blood stream [4]. Guanylin and
uroguanylin induce natriuresis, kaliuresis, and diuresis in
the kidney [4, 5]. Natriuresis produced by oral salt load
is decreased in uroguanylin-deficient mice [6], which sug-
gests that uroguanylin and guanylin are intestinal natri-
uretic peptides. Both activate guanylate cyclase C (GC-C)
which was first described as receptor for the heat-stable
enterotoxin of Escherichia coli (STa) [7]. Mimicking the
physiologic effects of guanylin and uroguanylin, STa
which has a higher affinity to GC-C produces secre-
tory diarrhea [8]. Activation of GC-C increases intra-
cellular cyclic guanosine monophosphate (cGMP) and
activates protein kinase G (PKG), which stimulates the
cystic fibrosis transmembrane regulator (CFTR) leading
to secretion of Cl−, HCO3−, and water in the intestine
[9–11].
GC-C–deficient mice (GC-C−/−) show resistance to
STa in the intestine, but guanylin, uroguanylin, and STa
still cause natriuresis, kaliuresis, and diuresis suggesting
the existence of a GC-C–independent signaling pathway
in the kidney [12]. In a human proximal tubule cell line, we
recently demonstrated that guanylin, uroguanylin, and
STa activate two signaling pathways: one involving GC-
C leading to increased cellular cGMP, the other involv-
ing the activation of a pertussis toxin–sensitive G protein
[13]. Both pathways lead to regulation of K+ conduc-
tances in these human proximal tubule cells.
The involvement of guanylin and uroguanylin in kid-
ney diseases is evident from the fact that uroguanylin
concentrations in plasma and urine are increased in pa-
tients with chronic renal failure [14] or nephrotic syn-
drome [15]. Guanylin and uroguanylin concentrations are
also increased in patients undergoing dialysis [14]. This
could be a consequence of kidney damage and therefore
reduced renal metabolism and excretion of these peptides
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and/or guanylin and uroguanylin are directly involved in
the development of renal diseases.
Guanylin and uroguanylin also play an important role
in the development of intestinal tumors. Shailubahai et
al [16] showed that oral application of uroguanylin leads
to a decrease in number and size of polyps in mice which
develop intestinal polyposis, proposing uroguanylin as a
novel drug in the therapy of intestinal tumors. Further,
guanylin and uroguanylin play a significant physiologic
and pathophysiologic role also in the reproductive and
lymphatic systems [17] and the lungs [18]. Uroguanylin,
intravenous or inhaled, inhibited bronchoconstriction
and mucus secretion in airways of guinea pig [19]. These
results led to the conclusion that uroguanylin is a possible
drug in asthma therapy.
Guanylin and uroguanylin were proposed as novel
drugs for different human diseases. Thus, further un-
derstanding of detailed renal actions of these peptides
especially in the human kidney is urgently needed. In
this study we show, for the first time, cellular actions of
guanylin and uroguanylin in isolated tubule segments.
Furthermore, these data are the first functional data
obtained from isolated human nephron segments. We
demonstrate that guanylin and uroguanylin change a
K+ conductance of principal cells of cortical collecting
ducts (CCD) and thereby alters the driving force for Na+
and water reabsorption. The pathway for guanylin and
uroguanylin in principal cells of human CCD is GC-C–
independent and involves an activation of phospholipase
A2 (PLA2).
METHODS
Human tissues
Healthy cortical pieces from human kidneys were ob-
tained from patients undergoing tumor nephrectomies.
In this study, 47 human kidneys during more than 3 years
were used. Thirty-eight kidneys were from male patients
with an average age of 62 ± 2 years (ranging from 32 to
80 years). Nine kidneys were from female patients with
an average age of 70 ± 5 years (ranging from 49 to 95
years). The ethics committee of the Universita¨tsklinikum
Mu¨nster approved the procedure, and written consent
was obtained from each patient. Renal tissue was sepa-
rated and stored in modified Ringer’s solution (described
below) on ice in the operation theater as soon as possi-
ble. After cooled transfer to the laboratory the isolation
procedure was started immediately.
Isolation of human nephron segments
Large quantities of individual tubules were isolated
for reverse-transcription-polymerase chain reaction (RT-
PCR) analysis as described before [20]. Small human
cortical kidney pieces were incubated in minimal essen-
tial medium (MEM) plus 5 mmol/L glycin, 480 IU/mL
trypsin inhibitor from soybean, 50 IU/mL DNAse, and
533 IU/mL collagenase type 2 (Worthington Biochem-
ical Corp., Lakewood, NJ, USA) for 60 to 100 minutes
at 37◦C with aeration (95% O2 and 5% CO2), resulting
in a tubule suspension. Specific nephron segments were
collected in MEM with 5 mmol/L glycin under 50× mag-
nification at 4◦C. For patch clamp experiments and mea-
surements of intracellular Ca2+, CCD were isolated using
the procedure described for rat kidney [21] and modi-
fied for human kidneys as follows. Cortical pieces from
human kidneys were incubated at 37◦C with MEM plus
5 mmol/L glycin, 26 mmol/L NaHCO3, 429 IU/mL col-
lagenase type 4 (Worthington Biochemical Corp.) and
4 IU/mL protease for 45 minutes. CCD segments were
collected in the above medium without enzymes but in
addition containing 50 g/L albumin and 1 lmol/L de-
oxycorticosterone acetate (DOCA) under 50× magni-
fication at 4◦C (DOCA solution). To enable sealing of
patch clamp pipettes with the plasma membrane and
at the same time allow access of the bath solution to
the luminal membrane CCD clusters were prepared us-
ing a Ca2+-free solution (MEM) [5 mmol/L glycin and
5 mmol/L ethyleneglycol tetraacetate (EGTA)] for 4 min-
utes at 4◦C [22]. Further, for patch clamp experiments,
clusters were incubated at 37◦C in DOCA solution for
at least 2 hours before the experiments were started to
increase the Na+ conductance of principal cells of CCD.
RT-PCR
Human kidney pieces, isolated nephron segments (ap-
proximately 40 mm), glomeruli (400 pieces) were lysed
in a 4 mol/L guanidium chloride buffer and total RNA
was isolated using the RNeasy kit (Qiagen, Hilden,
Germany). cDNA was synthesized by reverse transcrip-
tase (Promega, Heidelberg, Germany) and subjected
to PCR reactions. For detecting mRNA for GC-C, we
used the primers 5′-GTATTGCCCTCTTTCTCTTTT
CC-′ and 5′-TTCCAGCCCCTCATTCAC-3′ (product
length 538 bp, annealing temperature 53◦C) and for
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
(used as positive control for the PCR reaction) 5′-
CTGCCCCCTCTGCTGATG-3′ and 5′-GTCCACCA
CCCTGTTGCTGT-3′ (614 bp, 56◦C). Reaction condi-
tions were as follows: 2 minutes at 94◦C, 30 seconds at
53◦C or 56◦C, and 1 minute at 72◦C, 1 cycle; 30 seconds at
94◦C, 30 seconds at 53◦C or 56◦C, and 1 minute at 72◦C,
30 cycles; and 30 seconds at 94◦C, 30 seconds at 53◦C
or 56◦C, and 10 minutes at 72◦C, 1 cycle. PCR reaction
products were analyzed by agarose gel electrophoresis
and verified by sequence analyses (Sequence Laborato-
ries, Go¨ttingen, Germany).
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Patch clamp studies
CCD clusters were fixed with a glass holding pipette in
the experimental chamber mounted on an inverted mi-
croscope (Axiovert 10) (Zeiss, Go¨ttingen, Germany). A
modified Ringer’s solution containing 145 mmol/L NaCl,
1.6 mmol/L K2HPO4, 0.4 mmol/L KH2PO4, 5 mmol/L D-
glucose, 1 mmol/L MgCl2, and 1.3 mmol/L calcium glu-
conate (pH 7.4) was used as bath solution. Experiments
were performed at 37◦C with a bath perfusion rate of 10
mL/min at a bath volume of 500 lL. Patch clamp pipettes
were filled with a solution containing 95 mmol/L potas-
sium gluconate, 30 mmol/L KCl, 4.8 mmol/L Na2HPO4,
1.2 mmol/L NaH2PO4, 5 mmol/L D-glucose, 1.3 mmol/L
calcium gluconate, 1.03 mmol/L MgCl2, and 1 mmol/L
adenosine triphosphate (ATP) (pH 7.2). To this solution
160 lmol/L nystatin was added to permeabilize the mem-
brane under the pipette. Membrane potential (Vm) was
measured with a patch clamp amplifier [23]. Due to the
high electrical coupling between principal cells and the
fact that seals were only obtained with pipette resistances
> 10 M reproducible recordings of effects on whole cell
currents were not possible.
Fluorescence measurements of intracellular Ca2+
The same experimental setup as described above but
in addition equipped with a fluorescence detecting sys-
tem with a photon-counting tube (Hamamatsu H 3460-
04, Herrsching, Germany) was used for measurements
of intracellular Ca2+. CCD clusters were incubated with
fura2-acetoxymethyl ester (1 lmol/L) for 30 minutes and
excited at 340 nm, 380 nm, and 360 nm. The fluorescence
ratio (340/380) was calculated. Experiments were con-
trolled and results analyzed with a computer system as
described before [24].
Materials
MEM was obtained from Gibco (Karlsruhe,
Germany). Guanylin and uroguanylin were purchased
from Peptide Institute (Osaka, Japan). AACOCF3 was
purchased from Biomol (Hamburg, Germany). All
other chemicals were obtained from Merk (Darmstadt,
Germany) or Sigma (Taufkirchen, Germany).
Statistics
Student paired t test was used with each effect com-
pared with its own averaged pre- and postcontrol values.
Data are given as mean values ± SEM with the num-
ber of experiments given in brackets. P < 0.05 was set as
significance level.
RESULTS
Electrophysiologic properties of human CCD
Vm of principal cells of human CCD was measured by
the slow-whole-cell patch clamp technique after incuba-
tion in DOCA solution for at least 2 hours. Principal cells
were identified by hyperpolarizations caused by the in-
hibitor of epithelial Na+ channels amiloride (1 lmol/L)
(−4.1 ± 0.4 mV) (N = 53) (Fig. 1A), as the epithelial
Na+ channel (ENaC) is present in CCD only in principal
cells [23]. Basal Vm of human principal cells of CCD was
–66 ± 2 mV) (N = 64). Increasing the extracellular K+
concentration by 15 mmol/L depolarized cells by 24 ± 1
mV) (N = 64) (Fig. 1A), which corresponds to a relative
K+ conductance of approximately 70%. The general K+
channel blocker Ba2+ (1 mmol/L) depolarized principal
cells by 20 ± 2 mV) (N = 18). The frequency distribution
of basal Vm is shown in Figure 1B and the correlation of
basal Vm with the depolarizations caused by this increase
in the K+ concentration in Figure 1C. The classic second
messenger involved in regulation of CCD water and Na+
conductance in the rat is cAMP [23, 25]. The membrane
permeable analogue 8Br-cAMP (100 lmol/L) depolar-
ized principal cells of human CCD (2.3 ± 0.7 mV) (N =
6).
Effects of guanylin and uroguanylin
Guanylin and uroguanylin (10 nmol/L) led to depolar-
izations of Vm of principal cells of human CCD (guanylin
3.3 ± 0.8 mV) (N = 12) (uroguanylin 3.4 ± 0.5 mV) (N =
18). These effects were immediate, reversible and reached
their maximum within 1 to 2 minutes (Fig. 2A and B).
These effects of guanylin and uroguanylin on principal
cells are summarized in Figure 2c.
GC-C is not present in human principal cells
cGMP is the second messenger for guanylin and
uroguanylin in the intestine [26, 27]. Therefore, we tested
if cGMP is involved in the signaling pathway of guanylin
and uroguanylin in principal cells of human CCD. Op-
posite to the depolarizations caused by guanylin and
uroguanylin, 8Br-cGMP (100 lmol/L), a membrane per-
meable analogue of cGMP, hyperpolarized principal cells
(−3.0 ± 0.2 mV) (N = 4) (Fig. 2B and C). As shown before
[13] mRNA for GC-C was detected in human proximal
tubules but was absent in human CCD (Fig. 3). These
results exclude cGMP and GC-C as part of the signaling
pathway for guanylin and uroguanylin in human principal
cells.
Guanylin and uroguanylin do not alter cellular
Ca2+ ([Ca2+]i)
An additional possible signaling partway for guanylin
and uroguanylin is Ca2+ and protein kinase C (PKC)
[28]. To determine the involvement of Ca2+ signal-
ing in the effects of guanylin and uroguanylin in hu-
man CCD we measured [Ca2+]i with the fluorescent
dye fura2- ester. Guanylin or uroguanylin did not sig-
nificantly increase [Ca2+]i in human CCD (Fig. 4A),
whereas prostanglandin E2 (PGE2) increased [Ca2+]i.
Sindic´ et al: Guanylin and uroguanylin effects in human CCD 1423
−80
−60
−40
−20
0
V m
,
 
m
V
A
Am (1 µmol/L)K+ increase
1 min
20
22
18
16
14
12
10
8
6
4
2
0
Fr
e
qu
en
cy
−100 −90 −80 −70 −60 −50 −40 −30
Vm, mV
B
40
45
35
30
25
20
15
10
5
0
∆ 
V m
,
 
m
V
−100 −90 −80 −70 −60 −50 −40 −30
Vm, mV
r = −0.84
C
Fig. 1. General electrophysiologic characteristics of principal cells of
human cortical collecting ducts (CCD). Vm was measured by the slow-
whole-cell patch clamp technique after incubation in deoxycortico-
Again as shown before for the rat [24] such changes in
[Ca2+]i do not significantly change Vm of principal cells
(Vm by PGE2 (−1.0 ± 0.3 mV) (N = 3). A summary
of these results is given in Figure 4B. Thus, changes of
Vm caused by guanylin and uroguanylin did not involve
changes in [Ca2+]i in human principal cells and vice versa.
Role of K+ channels in the action of guanylin
and uroguanylin
Changes of Vm could be caused by changes in Na+, K+,
or Cl− conductances. To identify the involvement of K+
conductances in the action of guanylin and uroguanylin
the general K+ channel blocker Ba2+ was used. Depo-
larizations caused by guanylin or uroguanylin were com-
pletely blocked by Ba2+ indicating the involvement of K+
conductances in the signaling pathway of these peptides
(Fig. 5).
Inhibition of the PLA2 blocked depolarizations
caused by uroguanylin
Arachidonic acid is covalently linked to glycerol in
the middle position of phospholipides and is liberated
by enzymatic PLA2-mediated hydrolysis. Arachidonic
acid inhibits renal outer medullary K+ channel (ROMK)
channels located at the luminal membrane of princi-
pal cells [29]. Here arachidonic acid (10 lmol/L) led
to depolarizations of Vm (10.0 ± 0.8 mV) (N = 3).
Since the effects of guanylin and uroguanylin are due
to changes in K+ conductances the involvement of PLA2
in the signaling pathway of these peptides was tested us-
ing AACOCF3, an inhibitor of PLA2. Depolarizations
caused by uroguanylin (10 nmol/L) were inhibited by
5 lmol/L AACOCF3 (Fig. 6). These results suggest an in-
volvement of PLA2 in the signaling pathway of guanylin
and uroguanylin in human principal cells.
DISCUSSION
The current understanding of the main physiologic
function of guanylin and uroguanylin is apparently to
couple renal electrolyte transport to intestinal transport
and increase renal Na+ excretion after ingestion of high
amounts of salt [6]. Their relevance for the K+ home-
ostasis of the body and its renal regulation has not been
discussed yet. The signaling pathways, receptors, and lo-
calization of actions of these peptides in the kidney are
still poorly understood. As these peptides seem to be
sterone acetate (DOCA) solution for at least 2 hours. (A) Original trace
showing depolarizations caused by an increase in the K+ concentration
from 3.6 to 18.6 mmol/L and the identification of a principal cell by the
amiloride (Am) (1 lmol/L) induced hyperpolarization. (B) Frequency
distribution of basal Vm which shows a Gaussian-like distribution. (C)
Correlation between Vm and depolarizations caused by an increase in
extracellular K+ from 3.6 mmol/L to 18.6 mmol/L (r = −0.84).
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Fig. 2. Effects of guanylin (GN) and uroguanylin (UGN) on Vm of
principal cells of human cortical collecting ducts (CCD). Vm was mea-
sured by the slow whole-cell patch clamp technique after incubation in
deoxycorticosterone (DOCA) solution for at least 2 hours. (A) Original
trace showing the depolarization of a principal cell caused by guanylin
(10 nmol/L). (B) Original trace showing the depolarization caused by
uroguanylin (10 nmol/L) and the opposite effect of 8Br-cyclic guano-
sine monophosphate (cGMP) (100 lmol/L). (C) Summarized effects of
guanylin, uroguanylin, and 8Br-cGMP on human principal cells (mean
± SEM, number of experiments given in brackets).
involved in various renal and extrarenal diseases [14–16,
19], they have been discussed for possible therapeutic use
[16, 19]. Therefore, detailed understanding of the mech-
anisms of their renal actions is urgently needed. Besides
earlier reports on saliuresis and diuresis caused by these
peptides in vivo or in vitro in the rat [5, 12], we recently
described, for the first time, renal effects of guanylin
and guanylin as well as of STa on the cellular level in
a human proximal tubule cell line [13]. The results from
this cell line suggest that these peptides reduce reabsorp-
tion along the proximal tubule. Clearance studies suggest
the collecting duct as another possible site of guanylin
and uroguanylin actions because this segment plays the
538 bp -
M 1 2 3 4 5 6
- 614 bp
Fig. 3. Reverse transcription-polymerase chain reaction (RT-PCR)
analysis of the expression of mRNA for guanylate cyclase C (GC-
C), which is not present in human cortical collecting ducts (CCD), but
present in proximal tubules. M, marker; lane 1, glomeruli; lane 2, prox-
imal tubules; lane 3, thick ascending limbs; lane 4, cortical collecting
ducts; lane 5, negative control (no cDNA); and lane 6, positive control
[glyceraldehyde-3-phosphate dehydrogenase (GAPDH)]. Representa-
tive sample of three similar experiments.
2.0
1.6
1.2
0.8C
ha
ng
es
 in
 fl
uo
re
sc
en
ce
ra
tio
,
 
34
0/
38
0
A
PGE2 UGN GN
1 min
0.08
0.06
0.04
0.02
0
Ch
an
ge
s 
in
 th
e 
flu
or
es
ce
nc
e 
ra
tio
,
 
34
0/
38
0
(3)
(100 nmol/L)
PGE2
(3)
(10 nmol/L)
GN
(3)
(10 nmol/L)
UGN
B
Fig. 4. Effects of guanylin (GN) and uroguanylin (UGN) on [Ca2+]i
in human cortical collecting ducts (CCD). CCD were incubated with
fura2-acetoxymethyl ester (1 lmol/L) for 30 min. (A) Original trace
showing the absence of effects of guanylin (10 nmol/L), uroguanylin
(10 nmol/L), and the effect of prostaglandin E2 (PGE2) (100 nmol/L)
as positive control. (B) Summary of the effects (mean ± SEM, number
of experiments given in brackets).
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Fig. 5. Role of K+ conductances in the action of guanylin (GN)
and uroguanylin (UGN). Vm was measured by the slow whole-cell
patch clamp technique after incubation in deoxycorticosterone acetate
(DOCA) solution for at least 2 hours. Depolarizations caused by both
peptides (10 nmol/L each) were blocked by Ba2+ (1 mmol/L). ∗P <
0.05 between effects of guanylin or uroguanylin in the presence of Ba2+
compared to control effects (mean ± SEM, paired experiments, number
of experiments given in brackets).
major role in the final regulation of Na+, K+, and water
excretion.
In this study we present, for the first time, functional
data of principal cells of freshly isolated human CCD us-
ing patch clamp and fura2 analysis of Vm and [Ca2+]i.
The accessibility of fresh human renal tissue for such
functional measurements is obviously very limited and
using healthy tissue surrounding renal tumors offers a
rather unique opportunity to isolate individual nephron
segments also for such studies. The isolation of CCD from
those tissue samples was modified from the method al-
ready described for the rat [21]. Basal Vm of human prin-
cipal cells was not different compared to basal Vm of rat
principal cells measured with the same technique [21].
Vm clearly correlates with the relative contribution of
the K+ conductance as predicted from the general cellular
model of principal cells which possesses K+ conductances
in the basolateral and luminal membrane and a luminal
Na+ conductance [23]. Whereas in the human proximal
tubule cell line (IHKE-1) guanylin and uroguanylin acti-
vated two signaling pathways leading to depolarizations
or hyperpolarizations of Vm [13], these peptides only de-
polarized principal cells of human CCD (Fig. 2). There-
fore, we assumed the existence of one receptor/signaling
pathways for guanylin and uroguanylin in the CCD. Since
cGMP is the second messenger for these peptides in the
intestine [26, 27] and at least for one pathway in the proxi-
mal tubule [13] we determined if cGMP plays a role in the
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Fig. 6. Effects of AACOCF3, an inhibitor of phospholipase A2 (PLA2)
on uroguanylin (UGN) effects. Vm was measured by the slow whole-
cell patch clamp technique after incubation in deoxycorticosterone
(DOCA) solution for at least 2 hours. ∗P < 0.05 between effects of
uroguanylin in the presence of AACOCF3 compared to control effects
(mean ± SEM, paired experiments, number of experiments given in
brackets).
signaling pathway of guanylin or uroguanylin in principal
cells of human CCD. Similar to the rat [21], cGMP hy-
perpolarized human principal cells of CCD (Fig. 2B and
C). Even more, mRNA for GC-C, the first receptor de-
scribed for these peptides in the intestine [26, 27] and also
expressed in human proximal tubules [13], was neither
present in human (Fig. 3) nor in mouse nor in rat CCD [30,
31]. These results suggest the existence of a cGMP- and
GC-C–independent signaling pathways for guanylin and
uroguanylin in the human CCD. This conclusion also ex-
plains why in GC-C–deficient mice guanylin still induces
natruiuresis and diuresis. The latter further demonstrates
that apparently the collecting duct is more relevant for the
renal actions of these peptides compared to the proximal
tubule.
Since Ca2+ and PKC were suggested as a possible ad-
ditional and cGMP-independent signaling pathway for
these peptides in the intestine [28] we, therefore, tested
if Ca2+ as a second messenger is involved in the ef-
fect of those peptides in human principal cells. However,
guanylin and uroguanylin did not change [Ca2+]i. This is
in line with the absence of effects of other Ca2+-activating
agonists on ion conductances in the rat CCD reported be-
fore [24] and shown here as well for the human CCD.
Depolarizations of principal cells can be the result of
an increase of the Na+ conductance or a decrease of K+
conductances. While the first would result in deceased
natriuresis, the latter by decreasing the driving force for
Na+ and water reabsorption would lead to natriuresis and
diuresis, as observed for guanylin and uroguanylin [4, 5,
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12]. To identify the involvement of K+ conductances in
the action of guanylin and uroguanylin the general K+
channel blocker Ba2+ was used. Depolarizations caused
by both peptides were inhibited in the presence of Ba2+
(Fig. 3) suggesting indeed an involvement of changes in
K+ conductances in the signaling pathways of guanylin
and uroguanylin in human CCD principal cells as shown
before by us for the human proximal tubule cell line [13].
The kind of preparation and analysis used here does not
allow to directly attribute these effects to either baso-
lateral or luminal K+ channels. The secretory K+ chan-
nel of the CCD is ROMK and ROMK-deficient mice
show natriuresis, kaliuresis, and diuresis [32] like animals
stimulated with guanylin or uroguanylin. This proposes
ROMK channels as possible final targets for guanylin and
uroguanylin. The second K+ channel expressed in the lu-
minal membrane, the maxi-K+ channel, is not active un-
der basal conditions and therefore can be excluded [33].
Furthermore, it is known that arachidonic acid inhibits
these ROMK channels located at luminal membrane of
principal cells of the rat [29] and therefore, it was not sur-
prising that in our study arachidonic acid depolarized hu-
man principal cells. Stimulation of PLA2 sets free arachi-
donic acid from phospholipides, structural components
of each plasma membrane. Inhibition of PLA2 with AA-
COCF3 blocked depolarizations caused by uroguanylin
suggesting the involvement of PLA2, arachidonic acid
and consequently ROMK channels in the signaling path-
way of these peptides in human principal cells of CCD.
In mouse CCD, receptors for guanylin and uroguanylin
are localized in the luminal membrane (own unpublished
observations). Uroguanylin is found in the urine and
mRNA for guanylin is expressed in CCD [31]. Taken to-
gether these data suggest luminal action of guanylin and
uroguanylin also in human CCD. A reduction in the K+
conductance of principal cells by inhibition of ROMK
channels and the consequent depolarizations will reduce
the driving force for Na+ and consecutive water reapsorp-
tion and thus, could at least in part explain the natriuresis
and diuresis seen in vivo with these peptides. Such a hor-
monal regulation of ROMK channels could be important
in kidney diseases when K+ secretion is impaired.
Guanylin and uroguanylin mediate their renal action
via a signaling pathway which is GC-C– and cGMP-
independent and thus, different from their signaling path-
way in the intestine. The described signaling pathway,
which involves PLA2 and arachidonic acid in human
CCD needs to be further investigated to evaluate its
specific role in pathophysiology such as nephritic syn-
drome. These findings, however, further suggest so far
unknown mechanisms for an involvement of guanylin or
uroguanylin in disorders of other organs like lungs, intes-
tine or reproductive organs. It is for sure necessary to be
considered when guanylin or uroguanylin are proposed
for the therapy of intestinal tumors [16] or asthma [19].
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